Skip to content
Influenza
-
MSD acquires Cidara Therapeutics for USD9.2B to strengthen influenza prevention pipeline
The pharmaceutical giant will pay USD221.50 per share in cash to purchase the US biotech company, which has developed an innovative platform called drug-Fc conjugates (DFCs).